Ayala Marcelo
Eye Department, Skaraborg Hospital Skövde, Sahlgrenska Academy, University of Gothenburg and Karolinska Institute, Skövde, Sweden.
SAGE Open Med. 2018 Jun 18;6:2050312118782262. doi: 10.1177/2050312118782262. eCollection 2018.
To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C.
This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Skaraborg Hospital, Skövde, Sweden. Complete success was defined as intraocular pressure ⩽18 mmHg (criterion 1) or intraocular pressure reduction ⩾30% (criterion 2) without eye drops postoperatively. Qualified success was defined using the same criteria (1 and 2), but patients were treated or untreated with eye-drops.
A total of 167 patients were included in this retrospective study, 83 patients in the no-mitomycin-C group and 84 patients in the mitomycin-C-treated group. No significant difference was found in intraocular pressure reduction between the mitomycin-C and no-mitomycin-C group (t-test; p = 0.19). Complete success using criterion 1 was 66.2% in no-mitomycin-C and 62.8% in mitomycin-C (p = 0.88); success using criterion 2 was 76.6% in the no-mitomycin-C and 64.2% in the mitomycin-C group (p = 0.21). Qualified success using criterion 1 was 71.4% in the no-mitomycin-C and 74.4% in the mitomycin-C group (p = 0.84); success using criterion 2 was 80.0% in the no-mitomycin-C and 84.4% in the mitomycin-C group. All included patients were born in Sweden.
Mitomycin-C seems to add no benefits to intraocular pressure reduction after primary trabeculectomies in a Swedish population.
评估两种不同手术技术（即有或没有丝裂霉素C的小梁切除术）后的长期随访结果。
本研究是对瑞典舍夫德斯卡拉堡医院眼科接受原发性小梁切除术患者的回顾性病历审查。完全成功定义为眼压≤18 mmHg（标准1）或眼压降低≥30%（标准2）且术后无需使用眼药水。合格成功的定义使用相同标准（1和2），但患者使用或未使用眼药水治疗。
本回顾性研究共纳入167例患者，其中丝裂霉素C未治疗组83例，丝裂霉素C治疗组84例。丝裂霉素C组和丝裂霉素C未治疗组在眼压降低方面未发现显著差异（t检验；p = 0.19）。使用标准1的完全成功率在丝裂霉素C未治疗组为66.2%，在丝裂霉素C治疗组为62.8%（p = 0.88）；使用标准2的成功率在丝裂霉素C未治疗组为76.6%，在丝裂霉素C治疗组为64.2%（p = 0.21）。使用标准1的合格成功率在丝裂霉素C未治疗组为71.4%，在丝裂霉素C治疗组为74.4%（p = 0.84）；使用标准2的成功率在丝裂霉素C未治疗组为80.0%，在丝裂霉素C治疗组为84.4%。所有纳入患者均出生于瑞典。
在瑞典人群中，丝裂霉素C似乎对原发性小梁切除术后降低眼压没有额外益处。
